| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 40 | 2022 | 1393 | 2.570 |
Why?
|
| Knee Prosthesis | 25 | 2022 | 395 | 2.180 |
Why?
|
| Joint Prosthesis | 17 | 2016 | 253 | 1.480 |
Why?
|
| Arthroplasty, Replacement, Hip | 18 | 2023 | 1413 | 0.940 |
Why?
|
| Prosthesis Failure | 24 | 2015 | 1204 | 0.830 |
Why?
|
| Arthroplasty, Replacement | 4 | 2013 | 309 | 0.690 |
Why?
|
| Knee Joint | 20 | 2022 | 1676 | 0.660 |
Why?
|
| Osteoarthritis | 19 | 2015 | 1063 | 0.620 |
Why?
|
| Shoulder Joint | 11 | 2010 | 742 | 0.610 |
Why?
|
| Elbow Joint | 5 | 2007 | 359 | 0.600 |
Why?
|
| Prosthesis Design | 19 | 2016 | 2114 | 0.590 |
Why?
|
| Posterior Cruciate Ligament | 6 | 2002 | 85 | 0.590 |
Why?
|
| Arthritis, Rheumatoid | 24 | 2020 | 3752 | 0.560 |
Why?
|
| Polyethylenes | 5 | 2016 | 290 | 0.520 |
Why?
|
| Arthritis | 5 | 2013 | 680 | 0.490 |
Why?
|
| Femur Head Necrosis | 4 | 2001 | 132 | 0.470 |
Why?
|
| Osteoarthritis, Knee | 9 | 2017 | 1234 | 0.460 |
Why?
|
| Synovial Membrane | 7 | 2020 | 532 | 0.450 |
Why?
|
| Reoperation | 25 | 2022 | 4300 | 0.450 |
Why?
|
| Range of Motion, Articular | 19 | 2016 | 1587 | 0.440 |
Why?
|
| Prosthesis Fitting | 3 | 2008 | 75 | 0.400 |
Why?
|
| Vitamin E | 1 | 2016 | 872 | 0.380 |
Why?
|
| Tibia | 5 | 2015 | 1069 | 0.320 |
Why?
|
| Biocompatible Materials | 2 | 2016 | 1683 | 0.320 |
Why?
|
| Osteolysis | 4 | 2006 | 275 | 0.310 |
Why?
|
| Arthroplasty | 3 | 2005 | 310 | 0.310 |
Why?
|
| Polyethylene | 3 | 2006 | 185 | 0.310 |
Why?
|
| Bone Malalignment | 1 | 2008 | 38 | 0.300 |
Why?
|
| Osteotomy | 7 | 2015 | 836 | 0.270 |
Why?
|
| Patella | 3 | 2016 | 315 | 0.270 |
Why?
|
| Thigh | 1 | 2006 | 240 | 0.250 |
Why?
|
| Benzylamines | 1 | 2006 | 246 | 0.240 |
Why?
|
| Developing Countries | 5 | 2022 | 2867 | 0.240 |
Why?
|
| Azetidines | 1 | 2006 | 142 | 0.240 |
Why?
|
| Osteoarthritis, Hip | 5 | 2011 | 409 | 0.230 |
Why?
|
| Femur | 4 | 2006 | 1307 | 0.230 |
Why?
|
| Cartilage, Articular | 4 | 2015 | 1099 | 0.230 |
Why?
|
| Dominican Republic | 7 | 2018 | 77 | 0.210 |
Why?
|
| Database Management Systems | 1 | 2004 | 257 | 0.210 |
Why?
|
| Pain, Postoperative | 4 | 2016 | 1737 | 0.200 |
Why?
|
| Intracranial Embolism | 1 | 2003 | 187 | 0.190 |
Why?
|
| Hip Joint | 6 | 2014 | 1014 | 0.190 |
Why?
|
| Hip Prosthesis | 5 | 2009 | 921 | 0.180 |
Why?
|
| Joint Instability | 3 | 2016 | 801 | 0.180 |
Why?
|
| Joint Diseases | 3 | 2013 | 459 | 0.180 |
Why?
|
| Treatment Refusal | 1 | 2004 | 429 | 0.180 |
Why?
|
| Radiography | 15 | 2008 | 6961 | 0.180 |
Why?
|
| Hip Dislocation | 1 | 2023 | 247 | 0.170 |
Why?
|
| Proteome | 2 | 2007 | 1857 | 0.170 |
Why?
|
| Aged | 58 | 2017 | 169042 | 0.170 |
Why?
|
| Arthroscopy | 3 | 2013 | 969 | 0.160 |
Why?
|
| Endocarditis | 1 | 2023 | 348 | 0.160 |
Why?
|
| Aged, 80 and over | 26 | 2017 | 58894 | 0.160 |
Why?
|
| Humans | 122 | 2023 | 760617 | 0.160 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 141 | 0.160 |
Why?
|
| Pharmacy | 1 | 2020 | 91 | 0.160 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2023 | 529 | 0.160 |
Why?
|
| Antigen-Antibody Complex | 3 | 2010 | 509 | 0.150 |
Why?
|
| Synovial Fluid | 3 | 2010 | 393 | 0.150 |
Why?
|
| Cementation | 3 | 2005 | 92 | 0.150 |
Why?
|
| Orthopedic Procedures | 2 | 2005 | 1265 | 0.150 |
Why?
|
| Middle Aged | 56 | 2017 | 220584 | 0.150 |
Why?
|
| Warfarin | 1 | 2006 | 1477 | 0.150 |
Why?
|
| Treatment Outcome | 23 | 2022 | 64568 | 0.150 |
Why?
|
| Tensile Strength | 2 | 2016 | 330 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2004 | 1066 | 0.140 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 1738 | 0.140 |
Why?
|
| Osteonecrosis | 4 | 2008 | 229 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1303 | 0.130 |
Why?
|
| Chondrocytes | 2 | 2015 | 792 | 0.130 |
Why?
|
| Fibroblasts | 3 | 2020 | 4137 | 0.130 |
Why?
|
| Follow-Up Studies | 20 | 2013 | 39063 | 0.130 |
Why?
|
| Cell Transplantation | 1 | 1997 | 472 | 0.120 |
Why?
|
| Orthopedics | 1 | 2004 | 898 | 0.120 |
Why?
|
| Joint Capsule | 1 | 1995 | 68 | 0.120 |
Why?
|
| Animal Assisted Therapy | 1 | 2014 | 13 | 0.120 |
Why?
|
| Male | 59 | 2020 | 360358 | 0.120 |
Why?
|
| Prostheses and Implants | 2 | 2013 | 1269 | 0.120 |
Why?
|
| Materials Testing | 2 | 2016 | 862 | 0.120 |
Why?
|
| Recovery of Function | 6 | 2017 | 2978 | 0.110 |
Why?
|
| Soft Tissue Injuries | 1 | 2015 | 172 | 0.110 |
Why?
|
| Decompression, Surgical | 1 | 1999 | 606 | 0.110 |
Why?
|
| Radius | 1 | 1996 | 441 | 0.110 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 92 | 0.110 |
Why?
|
| Female | 58 | 2022 | 392148 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2023 | 1579 | 0.110 |
Why?
|
| Postoperative Complications | 13 | 2015 | 15612 | 0.100 |
Why?
|
| Program Evaluation | 3 | 2018 | 2486 | 0.100 |
Why?
|
| Gastroenteritis | 9 | 1978 | 236 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 2568 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 7995 | 0.100 |
Why?
|
| Mental Health Services | 1 | 2023 | 1717 | 0.100 |
Why?
|
| Dinoprostone | 4 | 2002 | 597 | 0.100 |
Why?
|
| Interleukin-1 | 4 | 2003 | 1248 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2006 | 4785 | 0.090 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2015 | 423 | 0.090 |
Why?
|
| Debridement | 3 | 2008 | 493 | 0.090 |
Why?
|
| Femur Neck | 2 | 2010 | 314 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 1810 | 0.090 |
Why?
|
| Femoracetabular Impingement | 1 | 2013 | 179 | 0.090 |
Why?
|
| Retrospective Studies | 20 | 2023 | 80566 | 0.090 |
Why?
|
| Bone Transplantation | 4 | 2006 | 927 | 0.090 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2010 | 30 | 0.090 |
Why?
|
| Adult | 36 | 2017 | 220969 | 0.090 |
Why?
|
| Bone Cements | 2 | 2008 | 325 | 0.090 |
Why?
|
| Bone Density | 3 | 2010 | 3548 | 0.080 |
Why?
|
| Foreign-Body Reaction | 1 | 1990 | 157 | 0.080 |
Why?
|
| Synovitis | 2 | 2004 | 217 | 0.080 |
Why?
|
| Iloprost | 1 | 2008 | 25 | 0.080 |
Why?
|
| Cartilage | 2 | 2004 | 806 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2013 | 2635 | 0.080 |
Why?
|
| Cartilage Diseases | 1 | 1990 | 157 | 0.080 |
Why?
|
| Nanocomposites | 1 | 2008 | 49 | 0.080 |
Why?
|
| Quality of Life | 4 | 2015 | 13347 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2004 | 8998 | 0.070 |
Why?
|
| Epoprostenol | 1 | 2008 | 247 | 0.070 |
Why?
|
| Health Planning | 1 | 2009 | 230 | 0.070 |
Why?
|
| Dogs | 4 | 2014 | 3838 | 0.070 |
Why?
|
| Postoperative Care | 2 | 2009 | 1467 | 0.070 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 233 | 0.070 |
Why?
|
| Pain Measurement | 5 | 2017 | 3546 | 0.070 |
Why?
|
| Fractures, Spontaneous | 1 | 2008 | 231 | 0.070 |
Why?
|
| Vitamin D Deficiency | 2 | 2008 | 1388 | 0.070 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2008 | 155 | 0.070 |
Why?
|
| Arthrodesis | 2 | 1990 | 186 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3567 | 0.060 |
Why?
|
| HIV Infections | 2 | 2023 | 17337 | 0.060 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2006 | 141 | 0.060 |
Why?
|
| Collagen Type II | 1 | 2006 | 148 | 0.060 |
Why?
|
| Hip Fractures | 2 | 2011 | 988 | 0.060 |
Why?
|
| Glycoproteins | 2 | 2010 | 2200 | 0.060 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 3239 | 0.060 |
Why?
|
| Hip Dislocation, Congenital | 1 | 2008 | 224 | 0.060 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 529 | 0.060 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 12043 | 0.060 |
Why?
|
| Perception | 1 | 2011 | 1198 | 0.060 |
Why?
|
| Methods | 3 | 2001 | 1065 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2009 | 767 | 0.060 |
Why?
|
| Borates | 1 | 2004 | 19 | 0.060 |
Why?
|
| Stifle | 1 | 2004 | 28 | 0.060 |
Why?
|
| Computer Storage Devices | 1 | 2004 | 9 | 0.060 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 2004 | 51 | 0.060 |
Why?
|
| Edema | 1 | 2008 | 765 | 0.060 |
Why?
|
| Quality Improvement | 3 | 2015 | 3797 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 1990 | 1389 | 0.060 |
Why?
|
| Motor Activity | 1 | 2014 | 2714 | 0.060 |
Why?
|
| Viruses, Unclassified | 4 | 1978 | 19 | 0.060 |
Why?
|
| Patient Participation | 1 | 2013 | 1443 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1790 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 2849 | 0.050 |
Why?
|
| Femoral Fractures | 2 | 2008 | 375 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 584 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 2004 | 150 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2008 | 487 | 0.050 |
Why?
|
| Inhalation | 1 | 2003 | 143 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2011 | 2024 | 0.050 |
Why?
|
| Actins | 1 | 2010 | 2050 | 0.050 |
Why?
|
| Boston | 4 | 2018 | 9313 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 315 | 0.050 |
Why?
|
| Osteoporosis | 2 | 2011 | 1604 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2013 | 4160 | 0.050 |
Why?
|
| Public Housing | 1 | 2023 | 140 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2006 | 829 | 0.050 |
Why?
|
| Internet | 2 | 2004 | 3090 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 4 | 2022 | 5491 | 0.050 |
Why?
|
| Age Factors | 4 | 2014 | 18381 | 0.050 |
Why?
|
| Surgical Wound Infection | 2 | 2008 | 1529 | 0.050 |
Why?
|
| Naproxen | 2 | 1992 | 100 | 0.050 |
Why?
|
| Macrophages, Peritoneal | 1 | 2002 | 238 | 0.050 |
Why?
|
| Bone Resorption | 2 | 1998 | 723 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 4007 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 794 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 2629 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 396 | 0.040 |
Why?
|
| Bone Diseases | 1 | 1984 | 418 | 0.040 |
Why?
|
| Fracture Fixation | 1 | 2002 | 366 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 3805 | 0.040 |
Why?
|
| Obesity | 2 | 2013 | 12933 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 2003 | 272 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 1002 | 0.040 |
Why?
|
| Arthralgia | 2 | 2014 | 461 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 612 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2009 | 2241 | 0.040 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2003 | 451 | 0.040 |
Why?
|
| Severity of Illness Index | 6 | 2014 | 15828 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2004 | 529 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 1984 | 553 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 2189 | 0.040 |
Why?
|
| Decision Making | 1 | 2013 | 3918 | 0.040 |
Why?
|
| Pelvis | 1 | 2023 | 732 | 0.040 |
Why?
|
| Thoracic Surgery | 1 | 2005 | 722 | 0.040 |
Why?
|
| Smoking | 1 | 2015 | 9050 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2005 | 991 | 0.040 |
Why?
|
| Inclusion Bodies, Viral | 2 | 1975 | 45 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 3451 | 0.040 |
Why?
|
| Organ Culture Techniques | 3 | 2010 | 794 | 0.040 |
Why?
|
| Immunity | 2 | 1984 | 994 | 0.040 |
Why?
|
| Joints | 2 | 2009 | 322 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 258 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 506 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 313 | 0.040 |
Why?
|
| Vitamin D | 2 | 2008 | 3302 | 0.040 |
Why?
|
| Stress, Mechanical | 3 | 2008 | 1674 | 0.040 |
Why?
|
| Time Factors | 6 | 2015 | 39913 | 0.040 |
Why?
|
| Periosteum | 1 | 1997 | 136 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2020 | 23416 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2023 | 22148 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 2745 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2008 | 1957 | 0.030 |
Why?
|
| Proteomics | 2 | 2009 | 3836 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2023 | 1330 | 0.030 |
Why?
|
| HIV | 1 | 2023 | 1579 | 0.030 |
Why?
|
| Animals | 15 | 2020 | 168201 | 0.030 |
Why?
|
| Femur Head | 2 | 1987 | 297 | 0.030 |
Why?
|
| Adolescent | 8 | 2012 | 88234 | 0.030 |
Why?
|
| Manometry | 2 | 1987 | 454 | 0.030 |
Why?
|
| Feces | 7 | 1978 | 1490 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2000 | 786 | 0.030 |
Why?
|
| Rabbits | 3 | 2004 | 4770 | 0.030 |
Why?
|
| Pain | 4 | 2017 | 5061 | 0.030 |
Why?
|
| Clinical Competence | 2 | 2015 | 4789 | 0.030 |
Why?
|
| Patellofemoral Joint | 1 | 2016 | 133 | 0.030 |
Why?
|
| Cephalosporins | 3 | 1970 | 198 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2022 | 2838 | 0.030 |
Why?
|
| Anticipation, Psychological | 1 | 2014 | 85 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 6520 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2022 | 12758 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2008 | 7402 | 0.030 |
Why?
|
| Pain Perception | 1 | 2014 | 196 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 634 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2005 | 3900 | 0.030 |
Why?
|
| Quality of Health Care | 2 | 2015 | 4321 | 0.030 |
Why?
|
| Incidence | 4 | 2016 | 21337 | 0.030 |
Why?
|
| Computer Simulation | 3 | 2015 | 6233 | 0.030 |
Why?
|
| Hypertension | 1 | 2013 | 8529 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 12447 | 0.030 |
Why?
|
| Probability | 2 | 2011 | 2475 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2016 | 9643 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1997 | 2112 | 0.030 |
Why?
|
| Cost of Illness | 2 | 2013 | 1935 | 0.030 |
Why?
|
| Particle Size | 2 | 2010 | 1648 | 0.020 |
Why?
|
| Hip | 1 | 2013 | 255 | 0.020 |
Why?
|
| Risk Factors | 7 | 2015 | 74115 | 0.020 |
Why?
|
| Extracellular Matrix | 2 | 2010 | 1718 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 861 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1998 | 929 | 0.020 |
Why?
|
| Culture Media | 2 | 1990 | 895 | 0.020 |
Why?
|
| Disability Evaluation | 2 | 2014 | 1835 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2013 | 550 | 0.020 |
Why?
|
| United States | 6 | 2023 | 72272 | 0.020 |
Why?
|
| Massachusetts | 1 | 2023 | 8833 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3370 | 0.020 |
Why?
|
| Cobalt | 1 | 1990 | 154 | 0.020 |
Why?
|
| Echocardiography | 1 | 2003 | 4987 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1995 | 768 | 0.020 |
Why?
|
| Microscopy, Electron | 6 | 2001 | 2561 | 0.020 |
Why?
|
| Survival Analysis | 2 | 1999 | 10073 | 0.020 |
Why?
|
| Chromium | 1 | 1990 | 132 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 998 | 0.020 |
Why?
|
| Humeral Fractures | 1 | 1992 | 282 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 704 | 0.020 |
Why?
|
| Rotation | 2 | 2006 | 517 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2003 | 18937 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 1813 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2000 | 2515 | 0.020 |
Why?
|
| Macrophages | 4 | 2010 | 5758 | 0.020 |
Why?
|
| Models, Economic | 1 | 2013 | 714 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 1722 | 0.020 |
Why?
|
| Young Adult | 4 | 2017 | 59179 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2008 | 180 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2013 | 2278 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2008 | 158 | 0.020 |
Why?
|
| Titanium | 1 | 1990 | 485 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2008 | 132 | 0.020 |
Why?
|
| Bone Marrow | 2 | 1987 | 2909 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 1058 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2018 | 3016 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3548 | 0.020 |
Why?
|
| Disease Models, Animal | 4 | 2010 | 18221 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1990 | 607 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 2871 | 0.020 |
Why?
|
| Antibody Formation | 3 | 1984 | 1390 | 0.020 |
Why?
|
| Benchmarking | 1 | 2013 | 1045 | 0.020 |
Why?
|
| Movement | 2 | 1991 | 1476 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2023 | 54360 | 0.020 |
Why?
|
| Phlebography | 1 | 1987 | 326 | 0.020 |
Why?
|
| Patient Selection | 1 | 1998 | 4237 | 0.020 |
Why?
|
| Aggrecans | 1 | 2006 | 89 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 944 | 0.020 |
Why?
|
| Wound Healing | 1 | 1997 | 2802 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1987 | 385 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 1989 | 383 | 0.020 |
Why?
|
| Models, Biological | 2 | 2013 | 9461 | 0.020 |
Why?
|
| Mice | 5 | 2020 | 81368 | 0.020 |
Why?
|
| Inflammation | 2 | 2020 | 10760 | 0.020 |
Why?
|
| Phagocytosis | 2 | 2002 | 1526 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 265 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 2214 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3723 | 0.020 |
Why?
|
| Autoantigens | 1 | 2009 | 888 | 0.020 |
Why?
|
| Knee | 1 | 2007 | 279 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 14648 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 3800 | 0.010 |
Why?
|
| Acetabulum | 1 | 2009 | 542 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 1738 | 0.010 |
Why?
|
| Cattle | 1 | 1990 | 3841 | 0.010 |
Why?
|
| Methylmethacrylates | 1 | 1984 | 67 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6807 | 0.010 |
Why?
|
| Comorbidity | 2 | 2013 | 10505 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1987 | 1496 | 0.010 |
Why?
|
| Health Surveys | 1 | 2014 | 4037 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6474 | 0.010 |
Why?
|
| Antibody Diversity | 1 | 1984 | 72 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1984 | 200 | 0.010 |
Why?
|
| Collagen | 1 | 1992 | 2634 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 943 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1984 | 138 | 0.010 |
Why?
|
| Virus Diseases | 4 | 1978 | 718 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 1186 | 0.010 |
Why?
|
| Prevalence | 2 | 2012 | 15689 | 0.010 |
Why?
|
| Cell Communication | 1 | 1990 | 1654 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 880 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2013 | 12943 | 0.010 |
Why?
|
| Poverty | 1 | 2014 | 2692 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2639 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2003 | 299 | 0.010 |
Why?
|
| Fractures, Ununited | 1 | 2003 | 175 | 0.010 |
Why?
|
| Viruses | 3 | 1975 | 374 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 1984 | 532 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8645 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2011 | 23972 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 6188 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 11069 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 851 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9604 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2017 | 41457 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2009 | 2115 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1984 | 734 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 14018 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1984 | 850 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 901 | 0.010 |
Why?
|
| Bone Plates | 1 | 2003 | 464 | 0.010 |
Why?
|
| Child | 3 | 2008 | 80079 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 36402 | 0.010 |
Why?
|
| Life Style | 1 | 2011 | 3904 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2008 | 1596 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2003 | 1848 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 20074 | 0.010 |
Why?
|
| Maryland | 2 | 1977 | 277 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2577 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4570 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2002 | 552 | 0.010 |
Why?
|
| Hospital Charges | 1 | 2000 | 350 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 1441 | 0.010 |
Why?
|
| Osteitis Deformans | 1 | 1998 | 54 | 0.010 |
Why?
|
| Life Tables | 1 | 1998 | 364 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1984 | 1329 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1998 | 139 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 22115 | 0.010 |
Why?
|
| Hypotension | 1 | 1984 | 878 | 0.010 |
Why?
|
| Postmenopause | 1 | 2007 | 2511 | 0.010 |
Why?
|
| Reoviridae | 2 | 1976 | 162 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 2003 | 931 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 4533 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 2897 | 0.010 |
Why?
|
| Receptors, Parathyroid Hormone | 1 | 1998 | 332 | 0.010 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2000 | 385 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2004 | 1189 | 0.010 |
Why?
|
| Lymphedema | 1 | 2003 | 523 | 0.010 |
Why?
|
| Rheumatic Diseases | 1 | 1984 | 649 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1998 | 283 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 14591 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 4919 | 0.010 |
Why?
|
| Cell Line | 2 | 2003 | 15576 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 525 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 13495 | 0.010 |
Why?
|
| Diarrhea, Infantile | 1 | 1976 | 100 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1984 | 2604 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5430 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2008 | 3411 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 1663 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 14389 | 0.010 |
Why?
|
| Antigens, Viral | 5 | 1978 | 987 | 0.010 |
Why?
|
| Osteoclasts | 1 | 1998 | 711 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 2202 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 1900 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7568 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3392 | 0.010 |
Why?
|
| Jejunum | 1 | 1975 | 472 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1998 | 1687 | 0.010 |
Why?
|
| Pronation | 1 | 1993 | 52 | 0.010 |
Why?
|
| Supination | 1 | 1993 | 70 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 1977 | 514 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2002 | 1884 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2005 | 3418 | 0.010 |
Why?
|
| Proteus | 2 | 1969 | 11 | 0.010 |
Why?
|
| Ulnar Nerve | 1 | 1993 | 102 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2007 | 26049 | 0.010 |
Why?
|
| Enterobacter | 2 | 1969 | 44 | 0.010 |
Why?
|
| Plastics | 1 | 1993 | 117 | 0.010 |
Why?
|
| Klebsiella | 2 | 1969 | 49 | 0.010 |
Why?
|
| Ulna | 1 | 1993 | 134 | 0.010 |
Why?
|
| Paralysis | 1 | 1993 | 250 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1984 | 3045 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1984 | 2238 | 0.010 |
Why?
|
| Humerus | 1 | 1993 | 272 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 9417 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 4473 | 0.010 |
Why?
|
| Antibodies, Viral | 3 | 1978 | 3150 | 0.010 |
Why?
|
| Linear Models | 1 | 2000 | 5866 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1977 | 2328 | 0.010 |
Why?
|
| Fracture Healing | 1 | 1992 | 445 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1969 | 153 | 0.000 |
Why?
|
| Pseudomonas | 1 | 1969 | 124 | 0.000 |
Why?
|
| Metals | 1 | 1993 | 719 | 0.000 |
Why?
|
| Hospitalization | 1 | 2008 | 10704 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1998 | 3998 | 0.000 |
Why?
|
| Rats | 1 | 2003 | 23717 | 0.000 |
Why?
|
| Hospitals | 1 | 2000 | 3877 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1984 | 9172 | 0.000 |
Why?
|
| Length of Stay | 1 | 2000 | 6418 | 0.000 |
Why?
|
| Streptococcus pyogenes | 1 | 1969 | 292 | 0.000 |
Why?
|
| Communication | 1 | 2000 | 3849 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1969 | 825 | 0.000 |
Why?
|
| Complement Fixation Tests | 2 | 1976 | 68 | 0.000 |
Why?
|
| Carcinoma | 1 | 1977 | 2327 | 0.000 |
Why?
|
| Hawaii | 2 | 1975 | 101 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1976 | 299 | 0.000 |
Why?
|
| Streptococcus pneumoniae | 1 | 1969 | 730 | 0.000 |
Why?
|
| Urinary Tract Infections | 1 | 1969 | 802 | 0.000 |
Why?
|
| Medicare | 1 | 2000 | 6765 | 0.000 |
Why?
|
| Kidney | 1 | 1977 | 7045 | 0.000 |
Why?
|
| Escherichia coli | 2 | 1969 | 4209 | 0.000 |
Why?
|
| Veins | 1 | 1984 | 767 | 0.000 |
Why?
|
| Staphylococcal Infections | 2 | 1984 | 1406 | 0.000 |
Why?
|
| Lung | 1 | 1977 | 9998 | 0.000 |
Why?
|
| Pan troglodytes | 1 | 1978 | 223 | 0.000 |
Why?
|
| Staphylococcus aureus | 1 | 1984 | 1457 | 0.000 |
Why?
|
| Eosinophilia | 2 | 1970 | 559 | 0.000 |
Why?
|
| Virus Cultivation | 1 | 1974 | 88 | 0.000 |
Why?
|
| Neoplasms | 1 | 1984 | 22131 | 0.000 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1984 | 2234 | 0.000 |
Why?
|
| Disease Outbreaks | 2 | 1974 | 1748 | 0.000 |
Why?
|
| Acute Disease | 2 | 1975 | 7237 | 0.000 |
Why?
|
| Cesium | 1 | 1973 | 36 | 0.000 |
Why?
|
| Capsid | 1 | 1976 | 433 | 0.000 |
Why?
|
| Phosphotungstic Acid | 1 | 1972 | 6 | 0.000 |
Why?
|
| Diarrhea | 2 | 1970 | 1317 | 0.000 |
Why?
|
| Immune Sera | 1 | 1972 | 605 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1974 | 816 | 0.000 |
Why?
|
| Blood | 1 | 1974 | 596 | 0.000 |
Why?
|
| Ohio | 1 | 1972 | 322 | 0.000 |
Why?
|
| Penicillin Resistance | 1 | 1970 | 74 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1974 | 2467 | 0.000 |
Why?
|
| Chlorides | 1 | 1973 | 665 | 0.000 |
Why?
|
| Cephalothin | 1 | 1969 | 28 | 0.000 |
Why?
|
| Bacteriuria | 1 | 1969 | 102 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1970 | 414 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1972 | 1081 | 0.000 |
Why?
|
| Cellulitis | 1 | 1970 | 209 | 0.000 |
Why?
|
| Penicillins | 1 | 1970 | 402 | 0.000 |
Why?
|
| Intestines | 1 | 1974 | 1909 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1970 | 1936 | 0.000 |
Why?
|
| Infant | 1 | 1976 | 36152 | 0.000 |
Why?
|